- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Morrisville Today
By the People, for the People
TransEnterix Faces Stiff Competition in Medical Device Robotics
Comparison shows rivals outperforming TransEnterix on key financial metrics
Published on Mar. 8, 2026
Got story updates? Submit your updates here. ›
A financial analysis comparing TransEnterix, a medical device company focused on robotic surgical systems, to its competitors reveals that TransEnterix is lagging behind its peers on several key metrics, including net margins, return on equity, and return on assets. The data also shows that TransEnterix has lower institutional and insider ownership compared to the overall 'Surgical, Medical, And Dental Instruments And Supplies' industry.
Why it matters
As a publicly traded company, TransEnterix's financial performance and competitive positioning are crucial factors for investors and the broader medical technology industry. This analysis highlights the challenges TransEnterix faces in a crowded and competitive market for robotic surgical systems.
The details
The data shows that TransEnterix has significantly lower net margins (-2,149.15%), return on equity (-83.74%), and return on assets compared to its competitors in the 'Surgical, Medical, And Dental Instruments And Supplies' industry. Additionally, TransEnterix has lower institutional (8.2%) and insider (3.1%) ownership compared to the industry averages (19.3% and 19.5% respectively). TransEnterix also has a higher beta of 2.56, indicating its stock price is more volatile than the S&P 500 index.
- The financial data is current as of March 8, 2026.
The players
TransEnterix, Inc.
A medical device company that develops and sells robotic surgical systems, including the Senhance System and SurgiBot System.
The takeaway
TransEnterix faces an uphill battle in the competitive medical device robotics market, as its financial performance lags behind its peers. The company will need to find ways to improve its profitability, operational efficiency, and market share to remain competitive and attractive to investors.
